Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
IPO Year: 2021
Exchange: NASDAQ
Website: alzamend.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2021 | $8.00 | Buy | Ascendiant Capital Markets |
Alzamend is developing AL001, a lithium product designed for enhanced safety and efficacy compared to currently available FDA-approved and marketed lithium therapies At a low dose, AL001 evidenced consistently higher lithium concentrations than lithium carbonate within critical brain regions comprising target tissue for efficacy, which may provide therapeutic benefits with less risk in multiple neurological disorders Data will guide upcoming "Lithium in Brain" Phase II clinical trials in partnership with Massachusetts General Hospital Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment o
Data confirm the positive topline results announced in June 2023 identifying a maximum tolerated dose as assessed by an independent safety review committee Identified dose is unlikely to require lithium therapeutic drug monitoring Data will guide upcoming "Lithium in Brain" Phase II clinical trials in partnership with Massachusetts General Hospital, which were announced in August 2024 Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announc
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has received formal written notice from The Nasdaq Stock Market, LLC's Office of General Counsel ("Nasdaq") that Alzamend has demonstrated compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"), which requires a minimum stockholders' equity of $2,500,000. As previously reported, on September 26, 2023, Alzamen
Fireside conversation to take place on October 17, 2024, at 1:30 PM ET Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that CEO Stephan Jackman will participate in a fireside chat at the upcoming Maxim Group Virtual Healthcare Conference. The conversation will take place with a senior member of Maxim Group's biotech research team on Thursday, October 17, 2024, at 1:30 pm ET. Mr. Jackman looks forward to providing an overview of Alzamen
Alzamend recently announced partnership with Massachusetts General Hospital for five phase II clinical trials of AL001, involving healthy human subjects and patients with Alzheimer's, BD, MDD and PTSD Alzamend has executed an agreement to provide sufficient capital over the next 18 months to finance the initiation and progression of AL001 and ALZN002 clinical trials Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today shared a letter from its C
Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will be conducted; the goal is to compare lithium in human brain and brain structures to identify a potentially ideal dose of AL001 that is safe and effective as current products Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it is partn
Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will be conducted; the goal is to compare lithium in human brain and brain structures to identify a potentially ideal dose of AL001 that is safe and effective as current products Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it is partn
Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will be conducted; the goal is to compare lithium in human brain and brain structures to identify a potentially ideal dose of AL001 that is safe and effective as current products Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it is partn
Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will be conducted; the goal is to compare lithium in human brain and brain structures to identify a potentially ideal dose of AL001 that is safe and effective as current products Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it is partn
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated July 30, 2024, informing Alzamend that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). In order to regain compliance with the Minimum Bid Price Requirement, Alzamend's common stock w
Ascendiant Capital Markets initiated coverage of Alzamend Neuro with a rating of Buy and set a new price target of $8.00
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board. During her tenure at the University of South Florida ("USF"), Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend's two product candidates, AL001 and AL002. AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic co-crystal under development as an oral treatment for patients with demen
8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
424B5 - Alzamend Neuro, Inc. (0001677077) (Filer)
8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
10-Q - Alzamend Neuro, Inc. (0001677077) (Filer)
8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
10-K - Alzamend Neuro, Inc. (0001677077) (Filer)
NT 10-K - Alzamend Neuro, Inc. (0001677077) (Filer)
8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
424B3 - Alzamend Neuro, Inc. (0001677077) (Filer)
EFFECT - Alzamend Neuro, Inc. (0001677077) (Filer)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
SC 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
5 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that Alzamend's board of directors approved a one-for-ten reverse stock split of Alzamend's common stock ("Common Stock") that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on July 16, 2024. Beginning with the opening of trading on July 16, 2024, the Company's Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the Co
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 15.67% to $0.32. The market value of their outstanding shares is at $17.5 million. Talphera (NASDAQ:TLPH) shares rose 12.64% to $0.92. The market value of their outstanding shares is at $15.6 million. Helius Medical Tech (NASDAQ:HSDT) shares moved upwards by 10.11% to $1.06. The market value of their outstanding shares is at $3.1 million. Clover Health Investments (NASDAQ:CLOV) stock rose 9.72% to $1.13. The company's market cap stands at $561.0 mil
Gainers Ainos (NASDAQ:AIMD) stock rose 54.8% to $1.27 during Friday's pre-market session. The market value of their outstanding shares is at $8.2 million. Longeveron (NASDAQ:LGVN) shares moved upwards by 34.15% to $3.61. The company's market cap stands at $22.9 million. Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 20.99% to $2.42. The market value of their outstanding shares is at $4.4 million. Moleculin Biotech (NASDAQ:MBRX) stock moved upwards by 17.24% to $5.1. The market value of their outstanding shares is at $11.7 million. Tonix Pharmaceuticals (NASDAQ:TNXP) shares moved upwards by 12.84% to $1.23. The company's market cap stands at $3.6 million. Molecular Partners (NASDAQ:MO
Gainers Vaxart (NASDAQ:VXRT) shares increased by 146.7% to $1.85 during Thursday's after-market session. The market value of their outstanding shares is at $327.1 million. Venus Concept (NASDAQ:VERO) stock rose 10.32% to $0.95. The company's market cap stands at $6.0 million. Vincerx Pharma (NASDAQ:VINC) stock moved upwards by 5.99% to $0.73. The market value of their outstanding shares is at $21.5 million. Kintara Therapeutics (NASDAQ:KTRA) shares rose 5.82% to $0.2. The company's market cap stands at $10.9 million. Beyond Air (NASDAQ:XAIR) shares moved upwards by 5.64% to $1.31. The company's market cap stands at $60.1 million. Soligenix (NASDAQ:SNGX) stock rose 5.42% to $4.38. The m
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), announced today that the Nasdaq Hearings Panel ("Panel") granted Alzamend's request to continue its listing on The Nasdaq Capital Market ("Nasdaq"), subject to Alzamend demonstrating compliance, on or before September 23, 2024, with Listing Rule 5550(b)(1), which requires stockholder equity of at least $2.5 million (the "Stockholder Equity Rule"), and satisfying all applicable requirements for continued li
Gainers Aethlon Medical (NASDAQ:AEMD) stock moved upwards by 129.0% to $2.7 during Friday's pre-market session. The company's market cap stands at $7.1 million. Novavax (NASDAQ:NVAX) shares rose 119.23% to $9.8. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 51.18% to $5.76. The company's market cap stands at $94.4 million. As per the news, the Q1 earnings report came out yesterday. Natera (NASDAQ:NTRA) shares moved upwards by 20.31% to $114.96. The market value of their outstanding shares is at $14.0 billion. The company's, Q1 earnings came out yesterday. XTL Biopharmaceu
On Thursday, Alzamend Neuro Inc (NASDAQ:ALZN) entered into a Securities Purchase Agreement with an institutional investor for the purchase and sale of 50 shares of its Series A Convertible Preferred Stock, the stated value of $10,000 per share in a registered direct offering, for $500,000. Also Read: EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year Additionally, the Investor agreed to purchase up to an additional 2,450 Preferred Shares, of which 50 shares will be purchased at the initial closing and the remaining Preferred Shares over some time, as outlined in the Agreement, for an aggregate purchase of up to $25 million of Pref
BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the third quarter ended September 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Third quarter 2022 highlights include: Total assets of $610.9 million as of September 30, 2022; Positive working capital of $25.7 million as of September 30, 2022; Cash and cash equivalents of $10.1 million as of September 30, 2022; Revenue from cryptocurrency mining of $3.9 million, compared to $0.3 million in the prior third fiscal quarter; Revenue from the Company's majority owned subsidiary, The Singing Machine Company, Inc. (NASDAQ:MICS)
BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company"), reported its financial results for the second quarter ended June 30, 2022 on its Form 10-Q filed with the Securities and Exchange Commission. Second quarter 2022 highlights include: Total assets of $596.3 million as of June 30, 2022; Positive working capital of $51.4 million as of June 30, 2022; Cash and cash equivalents of $24.1 million as of June 30, 2022; Revenue from cryptocurrency mining of $4.0 million, compared to $0.3 million in the prior second fiscal quarter; Revenue from hotel operations of $4.6 million, compared to $0 in the prior second fiscal quarter; Revenue from lendi
The Company Grows Revenue by 120% to $52 Million and Ends the Year with $490 Million in Assets BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company") today announced its financial results for the year ended December 31, 2021 contained within its Form 10‑K filed with the Securities and Exchange Commission. Year ended December 31, 2021 highlights: Revenue of $52.4 million, an increase of 120% from $23.9 million in the prior fiscal year; Revenue from lending and trading activities of $16.9 million due to the allocation of capital to Digital Power Lending, LLC ("DP Lending"); Revenue from trading activities during the year ended December 31, 2021
IND Submission for Combined AL002 Phase 1/2 Clinical Trial Expected in Second Quarter of 2022 Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received confirmation that topline data for its Phase 1 clinical trial for AL001 for dementia related to Alzheimer's will be delivered mid- to late-December 2021. The Phase 1 first-in-human study is for the purpose of determining potential clinically safe and appropriate dosing for AL001 in a planned Phase 2 multiple ascending dose study. AL001 is a lithium-deliv
Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company (the "Company"), today announced its financial results for the three and nine months ended September 30, 2021. Nine months ended September 30, 2021 highlights: Revenue of $44.6 million, an increase of 167% from $16.7 million in the prior nine-month period; Revenue from lending and trading activities of $19.6 million due to the allocation of capital to DP Lending; Revenues from our trading activities during the nine months ended September 30, 2021 included significant net gains on equity securities, including unrealized gains and losses from market price changes. These gains and losses have caused and will continue to
Q2 2021 Revenue of $62.1 Million, up 1050% From the Prior Year's Quarter Q2 2021 Net Income of $42.2 Million Compared to a $1.4 Million Loss in the Prior Year's Quarter Total Assets of More Than a Quarter of a Billion Dollars ($259.1 Million) Ault Global Holdings, Inc. (NYSE:DPW) a diversified holding company (the "Company"), today announced its financial results for the second quarter ended June 30, 2021. Q2-2021 highlights Revenue of $62.1 million, an increase of 1050% from $5.4 million in the prior second fiscal quarter; Revenue from lending and trading activities of $53.3 million due to the allocation of capital to the Company's wholly owned subsidiary, Digital Power Lending, LL